Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA (R) (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).

Trial Profile

Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA (R) (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms CLEAREST
  • Sponsors Merck Serono
  • Most Recent Events

    • 26 Sep 2011 According to the EudraCT record, this trial is recruiting in France, but has prematurely ended in Germany, Austria, Netherlands and Portugal.
    • 23 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top